Key result
Off-label percutaneous valve-in-valve TAVI successfully treated a high-surgical-risk patient with prosthetic valve dysfunction secondary to endocarditis, yielding good function at 6 months.
Case Report (n=1)
No
Off-label valve-in-valve TAVI may be a feasible treatment for severe valvular insufficiency secondary to previous infective endocarditis in a biological prosthetic aortic valve after ruling out active infection.
May support off-label ViV TAVI for select post-endocarditis prosthetic dysfunction; hypothesis-generating and leaves open need for prospective data.
We present the case of a 69-year-old man with an aortic biological prosthetic valve. In May 2019, the patient experienced increasing dyspnea and fatigue: A diagnosis of prosthetic aortic valve dysfunction was made, leading to severe valvular insufficiency. The dysfunction of the prosthetic valve seemed to be linked to a previous infective endocarditis: after ruling out active endocarditis, the patient was treated with an off-label valve-in-valve transcatheter aortic valve implantation.
No takes yet. Share an insight, caveat, or question.
Giuseppe et al. (2022) conducted a case report in Aortic biological prosthetic valve dysfunction secondary to endocarditis (n=1). Percutaneous Valve-in-Valve Transcatheter Aortic Valve Implantation (ViV TAVI) was evaluated on Prosthesis function and clinical improvement. Off-label percutaneous valve-in-valve TAVI successfully treated a high-surgical-risk patient with prosthetic valve dysfunction secondary to endocarditis, yielding good function at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: